Reading focus
Syllabus: How Does Depression Arise and Recur?
Interpret the overall randomized result before considering the exploratory inflammatory subgroup.
Why you’re reading it. Test how far a plausible pathway can carry a treatment prediction, and where a new hypothesis requires new data.
A question to consider. How should the negative overall result and data-selected subgroup affect your confidence in different claims from the preceding review?
Why this reading
A plausible biological pathway does not guarantee that targeting it improves an outcome. Raison and colleagues test an anti-inflammatory intervention and examine whether initial inflammation changes the pattern of response. The trial makes the distinction between an overall result, a proposed moderator, and an exploratory subgroup especially consequential.
Before you read
Infliximab blocks tumor necrosis factor, an immune signaling protein. C-reactive protein is a marker associated with inflammation, not a diagnosis of an inflammatory cause of depression. A moderator describes variation in a treatment effect. Selecting a subgroup threshold after seeing data can produce a promising pattern that needs a separate test.
Read for
- Identify the randomized comparison, primary symptom outcome, and overall result before interpreting biomarker subgroups. Which claims were proposed beforehand, and which details emerged from the data?
- Follow the distinction between a continuous biomarker interaction and dividing participants at a selected threshold. Consider subgroup size, uncertainty, and the number of comparisons.
- Examine the participants’ diagnoses and treatment histories. Does this sample represent unipolar depression alone, or all people with depressive symptoms?
Consider afterwards
- How would you design a follow-up trial that fairly tests the suggested high-inflammation subgroup without selecting the threshold again from its results?
- Does a negative overall treatment result rule out every role for inflammation? What narrower conclusion does the experiment support?
Editorial context
The 60-person, 12-week trial detected no overall depression benefit and included nine participants with bipolar depression. Although biomarker moderation was hypothesized, the greater-than-5 mg/L cutoff was chosen from the observed data; the subgroup response comparison was not statistically significant. These exploratory observations do not validate an individual treatment-selection rule. The study tests one intervention in a particular sample, not every immune pathway or every depressive condition.